X0202 SCHEDULE 13G 0001858703 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 03/31/2026 0002035832 Aktis Oncology, Inc. 01021M104 17 Drydock Avenue, Suite 17-401,Boston, Massachusetts 02210 Boston MA 02210 Rule 13d-1(b) Blue Owl Capital Holdings LP DE 3161348.00 0.00 3161348.00 0.00 3161348.00 5.92 PN The reported percentage is calculated based on 53,403,173 shares of Common Stock outstanding as of March 10, 2026, as reported on the Issuer's 10-K filed with the Securities and Exchange Commission on March 30, 2026. Aktis Oncology, Inc. 17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210 This statement is filed by Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person." 399 Park Avenue, New York, New York 10022 See response to row 4 on the cover page. N IA See response to row 9 on the cover page. Pursuant to Rule 13d-4 of the Act, the Reporting Person declares that filing this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of the reported securities, for purposes of Section 13(d) and/or Section 13(g) or for any other purpose. See response to row 11 on the cover page. See response to row 5 on the cover page. See response to row 6 on the cover page. See response to row 7 on the cover page. See response to row 8 on the cover page. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Blue Owl Capital Holdings LP /s/ Karen Hager 05/13/2026